Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1001-1007

  Markman, M ^a   Bundy, B N ^a   Alberts, D S ^a   Fowler, J M ^a   Clark Pearson, D L ^a   Carson, L F ^a   Wadler, S ^a   Sickel, J ^a  

^a GOG Administrative Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NEUTROPENIA; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 0035865144     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1001     Document Type: Article

References (25)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ill and stage IV ovarian cancer
2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
3. Intraperitoneal therapy of ovarian cancer
4. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
5. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: A pilot trial with ten-year follow-up
6. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
7. Creatinine clearance: Bedside estimate
8. Sample-sizes for the Proportional Hazards Regression Model
9. Nonparametric estimation from incomplete observations
10. Evaluation of survival data and two new rank order statistics arising in its consideration
11. Regression model and life tables (with discussion)
12. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer
13. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy
14. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy
15. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
16. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: Lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon
17. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: A Gynecologic Oncology Group study
18. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study
19. A randomized trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals
20. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
21. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer: Scottish Gynecology Cancer Trials Group
22. Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study
23. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study
24. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A Gynecologic Oncology Group study